Evidence map›Paper›PMID 40189284›Full record

GuidelineMagnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine2025

Practical Brain MRI Guidelines for Anti-Aβ Antibody Treatment in Early Symptomatic Alzheimer's Disease.

Shingo Kakeda, Yukio Miki, Kohsuke Kudo, Harushi Mori, Aya M Tokumaru, Osamu Abe, Shigeki Aoki, Working Group for Brain MRI Guidelines for Anti-Aβ Antibody Treatment from The Japan Radiological Society, The Japanese Society for Neuroradiology, and The Japanese Society for Magnetic Resonance in Medicine

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shingo KakedaDepartment of Radiology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.
Yukio MikiDepartment of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Kohsuke KudoDepartment of Diagnostic Imaging, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
Harushi MoriDepartment of Radiology, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Aya M TokumaruDepartment of Diagnostic Radiology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan.
Osamu AbeDepartment of Radiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Shigeki AokiDepartment of Neurophysiology, Juntendo University School of Medicine, Tokyo, Japan.
Working Group for Brain MRI Guidelines for Anti-Aβ Antibody Treatment from The Japan Radiological Society, The Japanese Society for Neuroradiology, and The Japanese Society for Magnetic Resonance in Medicine

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThese guidelines aim to support MRI diagnosis in patients receiving anti-amyloid β (Aβ) antibody treatment without restricting treatment eligibility. MATERIALS AND

methodsThese guidelines were collaboratively established by Japan Radiological Society, The Japanese Society of Neuroradiology, and Japanese Society for Magnetic Resonance in Medicine by reviewing existing literature and the results of clinical trials.

resultsFacility standards should comply with the "Optimal Use Promotion Guidelines" of Japan, and physicians should possess comprehensive knowledge of amyloid-related imaging abnormalities (ARIA) and expertise in brain MRI interpretation. The acquisition of knowledge regarding amyloid-related imaging abnormalities, brain MRI, anti-Aβ antibody introduction, and post-treatment diagnosis are also recommended.

conclusionThese guidelines facilitate the accurate diagnosis and effective management of ARIA; ensure the safe administration of anti-Aβ drugs; and provide a framework for MRI facilities, includes staffing requirements and the use of MRI management systems.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBrainMagnetic Resonance ImagingHumansJapanAmyloid beta-PeptidesAlzheimer’s diseaseamyloid-related imaging abnormalitiesanti-amyloid beta antibody treatmentbrainguidelinesmagnetic resonance imaging

Identifiers

PMID40189284
PMCPMC12772267

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.